Diagnostic importance of circulating DNA fragments in oncology;Diagnostische bedeutung zirkulierender DNA- fragmente in der onkologie

LaboratoriumsMedizin

Volumn 29, Issue 2, 2005, Pages 113-129

  Holdenrieder, Stefan ^a   Von Pawel, Joachim ^b   Schalhorn, Andreas ^a   Stieber, Petra ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

Apoptosis; Cancer; Cell death; Diagnosis; DNA; Monitoring; Prediction; Prognosis; Therapy

Indexed keywords

DNA FRAGMENT;

APOPTOSIS; CANCER DIAGNOSIS; CORRELATION ANALYSIS; CYTOTOXICITY; DIFFERENTIAL DIAGNOSIS; EPIGENETICS; INFLAMMATION; ISCHEMIA; MEASUREMENT; MONITORING; MUTATION; NUCLEOSOME; ONCOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS;

EID: 23644456390     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/JLM.2005.019     Document Type: Review

References (146)

1. Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999;98:285-94.
2. Nelson SM, Ferguson LR, Denny WA. DNA and the chromosome-varied targets for chemotherapy. Cell Chromosome 2004;3:2.
3. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251-60.
4. Luger K. Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev 2003;13:127-35.
5. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
6. Hagmann M. How chromatin changes its shape. Science 1999;285:1200-2.
7. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.
8. Bjorklund S, Almouzni G, Davidson I, Nightingale KP, Weiss K. Global transcription regulators of eukaryotes. Cell 1999;96:759-67.
9. Boeger H, Griesenbeck J, Strattan JS, Kornberg RD. Nucleosomes unfold completely at a transcriptionally active promoter. Mol Cell 2003;11:1587-98.
10. Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR. Circulating nucleic acids and apoptosis. Ann N Y Acad Sci 2001;945:239-49.
11. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
12. Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2000;906:161-8.
13. Fadeel B, Orrenius S, Zhivotovsky B. Apoptosis in human disease: a new skin for the old ceremony? Biochem Biophys Res Commun 1999;266:699-717.
14. Holdenrieder S, Stieber P. Apoptotic markers in cancer. Clin Biochem 2004;37:605-17.
15. Leist M, Jäätelä M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001;2:1-10.
16. Nicotera P, Leist M, Single B, Volbracht C. Execution of apoptosis: converging or diverging pathways? Biol Chem 1999;380:1035-40.
17. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26.
18. Wyllie AH. Cell death: the significance of apoptosis. Int Rev Cytol 1980;68:251-306.
19. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995;146:3-15.
20. Formigli L, Papucci L, Tani A, Schiavone N, Tempestini A, Orlandini GE, et al. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell Physiol 2000;182:41-9.
21. Tanner JE. Nucleosomes activate NF-kappaB in endothelial cells for induction of the proangiogenic cytokine IL-8. Int J Cancer 2004;112:155-60.
22. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-95.
23. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
24. Krammer PH. CD95 (APO-1/Fas)-mediatied apoptosis: live and let die. Adv Immunol 1999;71:163-210.
25. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:43-50.
26. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, et al. Cell death: apoptosis versus necrosis [review]. Int J Oncol 2002;21:165-70.
27. Hengartner MO. Apoptosis: Corraling the corpses. Cell 2001;104:325-8.
28. Halicka HD, Bedner E, Darzynkiewicz Z. Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis. Exp Cell Res 2000;260:248-56.
29. van Nieuwenhuijze AE, van Lopik T, Smeenk RJ, Aarden LA. Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus. Ann Rheum Dis 2003;62:10-4.
30. Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l'homme. CR Acad Sci Paris 1948;142:241-3.
31. Steinman CR. Free DNA in serum and plasma from normal adults. J Clin Invest 1975;56:512-5.
32. Sorenson GD, Pribish DM, Valone PH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994;1:67-71.
33. Anker P. Quantitative aspects of plasma/serum DNA in cancer patients. Ann N Y Acad Sci 2000;906:5-7.
34. Amoura Z, Piette JC, Chabre H, Cacoub P, Papo T, Wechsler B, et al. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum 1997;40:2217-25.
35. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983;51:2116-20.
36. Holdenrieder S, Stieber P, Bodenmueller H, Fertig G, Fuerst H, Schmeller N, et al. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001;39:596-605.
37. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
38. Maebo A. Plasma DNA level as a tumor marker in primary lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 1990;28:1085-91.
39. Fournie GJ, Courtin JP, Laval F, Chale JJ, Pourrat JP, Pujazon MC, et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995;91:221-7.
40. Kuroi K, Tanaka C, Toi M. Plasma nucleosome levels in node-negative breast cancer patients. Breast Cancer 1999;6:361-4.
41. Holdenrieder S, Stieber P, Foerg T, Kuehl M, Schulz L, Busch M, et al. Apoptosis in serum of patients with solid tumours. Anticancer Res 1999;19:2721-4.
42. Kuroi K, Tanaka C, Toi M. Clinical significance of plasma nucleosome levels in cancer patients. Int J Oncol 2001;19:143-8.
43. Holdenrieder S, Stieber P, Bodenmueller H, Busch M, Fertig G, Fuerst H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 2001;95:114-20.
44. Holdenrieder S, Stieber P, Bodenmueller H, Busch M, von Pawel J, Schalhorn A, et al. Circulating nucleosomes in serum. Ann N Y Acad Sci 2001;945:93-102.
45. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-8.
46. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treatment Rev 2002;28:255-71.
47. Trejo-Becerril C, Perez-Cardenas E, Trevino-Cuevas H, Taja-Chayeb L, Garcia-Lopez P, Segura-Pacheco B, et al. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients. Int J Cancer 2003;104:663-8.
48. Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 2003;103:149-52.
49. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003;21:3902-8.
50. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
51. Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, Luketich JD, et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 2005;51:113-8.
52. Gormally E, Hainaut P, Caboux E, Airoldi L, Autrup H, Malaveille C, et al. Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer 2004;111:746-9.
53. Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003;31:1947-51.
54. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46:319-23.
55. Lam NY, Rainer TH, Chan LY, Joynt GM, Lo YM. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem 2003;49:1286-91.
56. Rainer TH, Wong LK, Lam W, Yuen E, Lam NY, Metreweli C, Lo YM. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem 2003;49:562-9.
57. Fishbein TM, Liu J, Wang L, Li Y, Boros P. Increased apoptosis is specific for acute rejection in rat small bowel transplant. J Surg Res 2004;119:51-5.
58. Atamaniuk J, Vidotto C, Tschan H, Bachl N, Stuhlmeier KM, Muller MM. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem 2004;50:1668-70.
59. Rumore P, Muralidhar B, Lin M, Lai C, Steinman CR. Hemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clin Exp Immunol 1992;90:56-62.
60. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998;17:89-97.
61. Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, et al. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 2002;48:1220-7.
62. Burlingame RW, Volzer MA, Harris J, Du Clos TW. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 1996;156:4783-8.
63. Gauthier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. J Immunol 1996;156:1151-6.
64. Emlen W, Mannik M. Clearance of circulating DNA-anti-DNA immune complexes in mice. J Exp Med 1982;155:1210-5.
65. Emlen W, Mannik M. Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. Clin Exp Immunol 1984;56:185-92.
66. Emlen W, Burdick G. Clearance and organ localization of small DNA anti-DNA immune complexes in mice. J Immunol 1988;140:1816-22.
67. Macanovic M, Lachmann PJ. Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 1997;108:220-6.
68. Amoura Z, Chabre H, Koutouzov S, Lotton C, Cabrespines A, Bach JF, Jacob L. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994;37:1684-8.
69. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994;94:184-92.
70. Amoura Z, Koutouzov S, Piette JC. The role of nucleosomes in lupus. Curr Opin Rheumatol 2000;12:369-73.
71. Odaka C, Mizuochi T. Role of macrophage lysosomal enzymes in the degradation of nucleosomes of apoptotic cells. J Immunol 1999;163:5346-52.
72. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000;407:784-8.
73. Du Clos TW, Marnell L, Zlock LR, Burlingame RW. Analysis of the binding of C-reactive protein to chromatin subunits. J Immunol 1991;146:1220-5.
74. Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep 1996;23:253-60.
75. Fournie GJ. Circulating DNA and lupus nephritis. Kidney Int 1988;33:487-97.
76. Garcia-Olmo D, Garcia-Olmo DC, Ontanon J, Martinez E, Vallejo M. Tumor DNA circulating in the plasma might play a role in metastasis. The hypothesis of the genometastasis. Histol Histopathol 1999;14:1159-64.
77. Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 2004;19:575-83.
78. Le Lann-Terisse AD, Fournie GJ, Benoist H. Nucleosome-dependent escape of tumor cells from natural-killer-mediated lysis: nucleosomes are taken up by target cells and act at a postconjugation level. Cancer Immunol Immunother 1997;43:337-44.
79. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice P. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987;23:707-12.
80. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-22.
81. Jen J, Wu L, Sidransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann N Y Acad Sci 2000;906:8-12.
82. Johnson PJ, Lo YM. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002;48:1186-93.
83. Sorenson GD. A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Ann N Y Acad Sci 2000;906:13-6.
84. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Nat Cancer Inst 2000;92:918-23.
85. Sorenson GD, Pribish DM, Valone PH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994;1:67-71.
86. Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N, et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998;4:1527-32.
87. Mulcahy HE, Lyautey J, Lederrey C, Chen XQ, Anker P, Alstead EM, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998;4:271-5.
88. Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997:112:1114-20.
89. Mulcahy HE, Lyautey J, Lederrey C, Chen XQ, Lefort F, Vasioukhin V, et al. Plasma DNA K-ras mutations in patients with gastrointestinal malignancies. Ann N Y Acad Sci 2000;906:25-8.
90. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM,Wyllie AH. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol 1997;181:401-4.
91. Schneider J, Presek P, Braun A, Löffler S, Woitowitz HJ. Serum ras (p21) as a marker for occupationally derived lung cancer? Clin Chem Lab Med 2000;38:301-5.
92. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994;86:774-9.
93. Bevilacqua RAU, Nunes DN, Stroun M, Anker P. The use of genetic instability as a clinical tool for cancer diagnosis. Sem Cancer Biol 1998;8:447-53.
94. Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med 1996;2:1033-5.
95. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med 1996;2:1035-7.
96. Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999;5:2689-92.
97. Gonzales R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ, et al. Microsatellite alterations and TP 53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol 2000;11:1097-104.
98. Coulet F, Blons H, Cabelguenne A, Lecomte T, Lacourreye O, Brasnu D, et al. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000;60:707-11.
99. Goessl C, Heicappell R, Munker R, Anker P, Stroun M, Krause H, et al. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res 1998;58:4728-32.
100. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 1997;3:621-4.
101. Mayall F, Fairweather S, Wilkins R, Chang B, Nicholls R. Microsatellite abnormalities in plasma of patients with breast carcinoma: concordance with the primary tumour. J Clin Pathol 1999;52:363-6.
102. Shaw JA, Smith BM, Walsh T, Johnson S, Primrose L, Slade MJ, et al. Microsatellite alterations plasma DNA of primary breast cancer patients. Clin Cancer Res 2000;6:1119-24.
103. Nakayama T, Taback B, Nguyen DH, Chi DD, Morton DL, Fujiwara Y, et al. Clinical significance of circulating DNA microsatellite markers in plasma of melanoma patients. Ann N Y Acad Sci 2000;906:87-98.
104. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
105. Chen XQ, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub E, et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999;5:2297-303.
106. Anker P, Stroun M. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia 2001;15:289-91.
107. Lo YM. Circulating nucleic acids in plasma and serum: an overview. Ann N Y Acad Sci 2001;945:1-8.
108. Herman JG. Hypermethylation of tumor suppressor genes in cancer. Sem Cancer Biol 2000;9:359-67.
109. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
110. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
111. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-74.
112. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
113. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
114. Herman JG, Baylin SB. Promoter-region hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol 2000;249:35-54.
115. Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 1999;5:1961-5.
116. Kopreski MS, Benko FA, Gocke CD. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci 2001;945:172-8.
117. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000;6:3823-6.
118. Poon LM, Leung TN, Lau TK, Lo YM. Presence of fetal RNA in maternal plasma. Clin Chem 2000;46:1832-4.
119. Gal S, Fidler C, Lo YM, Chin K, Moore J, Harris AL, Wainscoat JS. Detection of Mammaglobin mRNA in the plasma of breast cancer patients. Ann N Y Acad Sci 2001;945:192-4.
120. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287:2017-9.
121. Sidransky D. Circulating DNA: What we know and what we need to learn. Ann N Y Acad Sci 2000;906:1-4.
122. Bianchi DW, Flint AF, Pizzimenti MF, Knoll JH, Latt SA. Isolation of fetal DNA from nucleated erythrocytes in maternal blood. Proc Natl Acad Sci USA 1990;87:3279-83.
123. Bianchi DW, Lo YM. Fetomaternal cellular and plasma DNA trafficking: the Yin and the Yang. Ann N Y Acad Sci 2001;945:119-31.
124. Sekizawa A, Samura O, Zhen DK, Falco V, Farina A, Bianchi DW. Apoptosis in fetal nucleated erythrocytes circulating in maternal blood. Prenat Diagn 2000;20:886-9.
125. Lambert NC, Stevens AM, Tylee TS, Erickson TD, Furst DE, Nelson JL. From the simple detection of microchimerism in patients with autoimmune diseases to its implication in pathogenesis. Ann N Y Acad Sci 2001;945:164-71.
126. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
127. Bianchi DW. Fetal DNA in maternal plasma: the plot thickens and the placental barrier thins. Am J Hum Genet 1998;62:763-4.
128. Leung TN, Zhang J, Lau TK, Hjelm NM, Lo YM. Maternal plasma fetal DNA as a marker for preterm labour. Lancet 1998;352:1904-5.
129. Lo YM. Fetal DNA in maternal plasma: biology and diagnostic applications. Clin Chem 2000;46:1903-6.
130. Poon LM, Leung TN, Lau TK, Lo YM. Prenatal detection of fetal Down's syndrome from maternal plasma. Lancet 2000;356:1819-20.
131. Zhong XY, Holzgreve W, Hahn S. Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia. Ann N Y Acad Sci 2001;945:138-40.
132. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59:5452-5.
133. Lo YM, Chan WY, Ng EK, Chan LY, Lai PB, Tam JS, et al. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res 2001;7:1856-9.
134. Lei KI, Chan LYS, Chan WY, Johnson PJ, Lo YM. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr Virus DNA in natural killer / T-cell lymphoma. Clin Cancer Res 2002;8:29-34.
135. Grinstein S, Preciado MV, Gattuso P, Chabay PA, Warren WH, De Matteo E, et al. Demonstration of Epstein-Barr Virus in carcinomas of various sites. Cancer Res 2002;62:4876-8.
136. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E, et al. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004;22:4157-64.
137. Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res 2002;8:3761-6.
138. Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, et al. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004;90:1211-5.
139. Lo YMD, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000;60:6878-81.
140. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10:5981-7.
141. Holdenrieder S, Stieber P. Therapy control in oncology by circulating nucleosomes. Ann N Y Acad Sci 2004;1022:211-6.
142. Kremer A, Wilkowski R, Holdenrieder S, Nagel D, Stieber P, Seidel D. Nucleosomes in serum of patients with pancreatic cancer during the course of radiochemotherapy. Tumour Biol 2005;26:44-9.
143. Lo YMD, Leung SF, Chan LY, Chan AT, Lo KW, Johnson PJ, Huang DP. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000;60:2351-5.
144. Lo YMD, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59:5452-5.
145. Holdenrieder S, Stieber P, Chan LY, Geiger S, Kremer A, Nagel D, et al. Circulating nucleic acids in plasma and serum - comparison of ELISA and quantitative PCR. Clin Chem 2003;49:35.
146. Holdenrieder S, Mueller S, Olaposi Y, Stieber P. Stability of nucleosomes in serum. Clin Chem 2003;49:39.